CORAL SPRINGS, Florida, March 2, 2015 /PRNewswire/ --
Cutting-edge biotech & nutraceutical products, science-based pharmaceuticals and healthy whole food nutrition products reveal technological advancements are in growing demand for treatments of lifestyle related disorders such as hyperglycemia, obesity, insulin level issues and other serious illnesses and health concerns. Nutraceutical and Biotech Companies in focus today are: RiceBran Technologies (NASDAQ: RIBT), Amira Nature Foods Ltd. (NYSE: ANFI), CEL-SCI Corporation (NYSE: CVM), Mondelez International, Inc. (NASDAQ: MDLZ) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC).
RiceBran Technologies (NASDAQ: RIBT) and (RIBTW) ("RBT"), a global leader in the production and marketing of value added products derived from rice bran, today announced the release of a claims substantiation analysis of the health benefits of RBT's proprietary rice bran based ingredients conducted by Medicus Research. RBT contracted Medicus Research, the premier contract research organization for the Dietary Supplement, Functional Foods and Botanical Drug industries, to perform a comprehensive analysis of independent studies conducted on behalf of RBT to substantiate numerous important health claims for its proprietary and process patented rice bran derivatives and products.
Read the full RIBT Press Release at: http://www.financialnewsmedia.com/profiles/ribt.html
The research from Medicus substantiates that RBT's RiBran™ and RiSolubles® products reduce hyperglycemia; improves insulin levels and insulin sensitivity; and increases adiponectin levels. The research also cites scientific evidence indicating that the Company's RiFiber™ product reduces total cholesterol, LDL cholesterol and triglycerides; reduces absorption of cholesterol; and reduces plasma lipid and lipoprotein cholesterol. The full report as well as links to clinical study findings can be found on RBT's home page at http://www.ricebrantech.com.
W. John Short, CEO & President of RBT commented, "As the consumer package goods industry focuses billions of dollars on healthy whole food nutrition, the ability to provide ingredients that can result in important front of label claims for these new products differentiates RBT from our competitors. Medicus Research is widely considered to be the leading provider of research and clinical trials for healthy, natural products and functional foods. We are excited that the team at Medicus has substantiated the health benefits of our rice bran based products. We plan to pursue additional studies with Medicus going forward."
In Biotech and Nutraceutical news and developments: Amira Nature Foods Ltd. (NYSE: ANFI), a leading global provider of branded packaged Indian specialty rice, will be showcasing a new organic range of rice at the Natural Products Expo West on March 6-8th in the United States, presented alongside a variety of flagship Amira products. Amira will have their new organic and natural dry rice range products on display at booth #5005 in Hall E of the Anaheim Convention Center. Amira will also have a variety of rice dishes to sample, as well as celebrity chef guest appearances at their booth to create an authentic Amira experience. Celebrity Chef Daniel Shemtob, founder of the Lime Truck and winner of the Food Network's The Great Food Truck Race, will make guest appearances at Amira's booth to share his tricks of the trade and culinary advice on creating inventive ready-to-eat dishes using Amira products.
CEL-SCI Corporation (NYSE: CVM) recently announced the Ministry of Health of the Republic of Belarus has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Belarus is the 21th country to approve CEL-SCI's Phase III trial. "This means that CEL-SCI has now reached a key milestone in this pivotal Phase III clinical trial, receiving clearance in the planned 20 countries in addition to the United States. Well over 10 countries have been added to the study since we dismissed the prior clinical research organization (CRO). With the very large increase in enrollment in the study under the new CRO, we now also see strong interest from doctors and clinical centers in other countries too. Therefore, we are working on further expanding this global trial beyond the 21 countries in which we are already cleared to conduct the study. We expect that expanding the geography of the trial will yet further accelerate patient recruitment," stated CEL-SCI Chief Executive Officer Geert Kersten.
Mondelez International, Inc. (NASDAQ: MDLZ) announced that, as part of its ongoing efforts to further focus its portfolio on snacking products, it has reached an agreement to sell its 50 percent interest in Ajinomoto General Foods, Inc. (AGF) to its joint venture partner, Ajinomoto Co., Inc. AGF manufactures and sells instant, ground and liquid coffee products as well as other beverages in Japan under brands mainly licensed by Mondelez International, including Blendy and Maxim. In May 2014, Mondelez International announced its intention to combine its coffee business with D.E Master Blenders 1753 to create the world's leading pure-play coffee company, to be named Jacobs Douwe Egberts (JDE). As part of this, Mondelez International's Japan joint-venture partner, Ajinomoto, was invited to join JDE. During these discussions, Ajinomoto expressed a strong interest in acquiring Mondelez International's shares in AGF.
On February 18, 2015, the Board of Directors of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) declared a quarterly cash dividend in the amount of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock. The cash dividend will be payable on May 1, 2015 to the holders of record of the Preferred Stock as of the close of business on April 17, 2015. The Board considered numerous factors in determining whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus. While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future quarterly dividends will be declared. CYCC closed up over 37% on Friday at $1.50 per share on over 24Mil shares by the market close.
In other business news and events: Shares of Herbalife Ltd. (NYSE: HLF) plunged by nearly 11% on Friday as investors digested the company's dimmer outlook for 2015. The company released its fourth quarter earnings after markets closed on Thursday. Going into the earnings announcement, investors appeared focused on whether the company could meet its own earnings projections. It did, posting adjusted earnings of $1.41 per share. Read the full report at http://www.forbes.com/sites/nathanvardi/2015/02/27/herbalife-shares-plunge-nearly-11-on-grim-2015-outlook/?utm_campaign=yahootix&partner=yahootix
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by RiceBran Technologies. by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com
SOURCE FN Media Group LLC